Predicting Restenosis of Drug-Eluting Stents Placed in Real-World Clinical Practice: Derivation and Validation of a Risk Model From the EVENT Registry

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Circulation. Cardiovascular Interventions

• Publication date

  2010-07-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCINTERVENTIONS.110.946939PMID 20606136
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial.

  2009cited by this paper
• Safety and Efficacy of Drug-Eluting and Bare Metal Stents: Comprehensive Meta-Analysis of Randomized Trials and Observational Studies

  2009cited by this paper
• Two-year results of paclitaxel-eluting stents in patients with medically treated diabetes mellitus from the TAXUS ARRIVE program.

  2009cited by this paper
• Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease.

  2009cited by this paper
• Converting the Informed Consent From a Perfunctory Process to an Evidence-Based Foundation for Patient Decision Making

  2008cited by this paper
• Impact of "off-label" utilization of drug-eluting stents on clinical outcomes in patients undergoing percutaneous coronary intervention.

  2008cited by this paper
• Drug‐eluting stent in saphenous vein graft lesions

  2008cited by this paper
• Differential outcomes after sirolimus-eluting stent implantation: comparing on-label versus off-label patients in the ‘real world’

  2008cited by this paper
• Two-year clinical follow up of coronary drug-eluting stent in patients at high risk for coronary restenosis.

  2008cited by this paper
• A comparison of bare-metal and drug-eluting stents for off-label indications.

  2008cited by this paper
• Four-year clinical follow-up of the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital registry.

  2008cited by this paper
• A Comparison of Bare-Metal and Drug-Eluting Stents for Off-Label Indications

  2008cited by this paper
• Drug-eluting stents versus bare metal stents for narrowing in saphenous vein grafts.

  2008cited by this paper
• Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial.

  2007cited by this paper
• Outcomes and complications associated with off-label and untested use of drug-eluting stents.

  2007cited by this paper
• Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents.

  2007cited by this paper
• On- versus off-label use of drug-eluting coronary stents in clinical practice (report from the American College of Cardiology National Cardiovascular Data Registry [NCDR]).

  2006cited by this paper
• Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes

  2006cited by this paper
• The Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial.

  2006cited by this paper
• Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial.

  2006cited by this paper
• Risk of Restenosis and Health Status Outcomes for Patients Undergoing Percutaneous Coronary Intervention Versus Coronary Artery Bypass Graft Surgery

  2005cited by this paper
• Design of a registry to characterize "real-world" outcomes of percutaneous coronary revascularization in the drug-eluting stent era.

  2005cited by this paper
• Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients: The Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial

  2005cited by this paper
• Impact of Sirolimus-Eluting Stents on Outcome in Diabetic Patients: A SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) Substudy

  2004cited by this paper
• Clinical and Angiographic Predictors of Restenosis After Percutaneous Coronary Intervention: Insights From the Prevention of Restenosis With Tranilast and Its Outcomes (PRESTO) Trial

  2004cited by this paper
• Presentation of multivariate data for clinical use: The Framingham Study risk score functions

  2004cited by this paper
• Outcomes in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention in the Current Era: A Report From the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial

  2004cited by this paper
• A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.

  2004cited by this paper
• Unrestricted Utilization of Sirolimus-Eluting Stents Compared With Conventional Bare Stent Implantation in the “Real World”: The R apamycin-E luting S tent E valuated A t R otterdam C ardiology H ospital (RESEARCH) Registry

  2004cited by this paper
• Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.

  2003cited by this paper
• Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials.

  2002cited by this paper
• Acceleration of restenosis by diabetes: pathogenetic implications.

  2001cited by this paper
• Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era.

  2001cited by this paper
• Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators.

  2000cited by this paper
• The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.

  2000cited by this paper
• Predictive factors of restenosis after coronary stent placement.

  1997cited by this paper
• Angioplasty for dilatation of complex coronary artery bifurcation stenoses.

  1985cited by this paper

• Outcomes of durable versus biodegradable polymer drug-eluting stents in patients with coronary artery disease

  2026cites this paper
• Paclitaxel‐Coated Balloon for the Management of In‐Stent Coronary Restenosis: An Updated Meta‐Analysis and Trial Sequential Analysis

  2025cites this paper
• Use of sirolimus‐coated balloon in de novo coronary lesions; long‐term clinical outcomes from a multi‐center real‐world population

  2024cites this paper
• Technological Advances Are Associated With Better Clinical Outcomes of Percutaneous Coronary Intervention in Patients With Unprotected Left Main Disease

  2024cites this paper
• Is the enthusiasm for Drug‐Coated balloon technology justified?

  2024cites this paper
• A risk score for predicting in-stent restenosis in patients with premature acute myocardial infarction undergoing percutaneous coronary intervention with drug-eluting stent

  2024cites this paper
• Serum Nuclear Factor Erythroid-2 Related Factor-2 (NRF2) as an Indicator of Oxidative Stress is Related to Coronary in-Stent Restenosis

  2023cites this paper
• Association of Endothelial Nitric Oxide Synthase and Angiotensin-Converting Enzyme Genes Polymorphism With In-Sent Restenosis of Bare Metal Stents vs Drug-Eluting Stents in Egyptians

  2023cites this paper
• A systematic review of clinical and biomechanical engineering perspectives on the prediction of restenosis in coronary and peripheral arteries.

  2023influential citation
• A Nomogram for Predicting In-Stent Restenosis Risk in Patients Undergoing Percutaneous Coronary Intervention: A Population-Based Analysis

  2022cites this paper
• Single-nucleotide polymorphism of ADRβ2 and CDKN1B genes in Egyptian patients with coronary artery in-stent restenosis

  2022cites this paper
• Mechanisms for the Superiority of Coronary Artery Bypass Grafting in Complex Coronary Artery Disease.

  2022cites this paper
• Response to pre-dilatation with POBA can predict target lesion revascularization after DCB angioplasty for de novo small coronary artery lesions

  2022cites this paper
• Random forest vs. logistic regression: Predicting angiographic in-stent restenosis after second-generation drug-eluting stent implantation

  2022cites this paper
• Investigation Into the Risk Factors Related to In-stent Restenosis in Elderly Patients With Coronary Heart Disease and Type 2 Diabetes Within 2 Years After the First Drug-Eluting Stent Implantation

  2022cites this paper
• Current and Future Applications of Artificial Intelligence in Coronary Artery Disease

  2022influential citation
• Long-term Outcomes of Clopidogrel Monotherapy versus Prolonged Dual Antiplatelet Therapy beyond 12 Months after Percutaneous Coronary Intervention in High-risk Patients

  2021cites this paper
• 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2021cites this paper
• Development and validation of a risk prediction nomogram for in-stent restenosis in patients undergoing percutaneous coronary intervention

  2021cites this paper
• 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2021cites this paper
• Early-, Late-, and Very Late-Term Prediction of Target Lesion Failure in Coronary Artery Stent Patients: An International Multi-Site Study

  2021influential citation
• A neural system dynamics modeling platform and its applications in randomized controlled trial data analysis

  2021cites this paper
• Long-term Outcome following Percutaneous Intervention of Intra-stent Coronary Occlusion and Evaluating the Different Treatment Modalities

  2021cites this paper
• The Rise of Open-Sourced Machine Learning in Small and Imbalanced Datasets: Predicting In-Stent Restenosis.

  2020cites this paper
• Low ankle brachial index predicts poor outcomes including target lesion revascularization during the long-term follow up after drug-eluting stent implantation for coronary artery disease.

  2020cites this paper
• A randomized comparison of a novel iopromide-based paclitaxel-coated balloon Shenqi versus SeQuent Please for the treatment of in-stent restenosis

  2020cites this paper
• Drug-eluting balloon: is it useful?

  2020cites this paper
• Clinical characteristics of early and late drug-eluting stent in-stent restenosis and mid-term prognosis after repeated percutaneous coronary intervention

  2020cites this paper
• Predictors for adverse outcomes of patients with recanalized chronic total occlusion lesion

  2020cites this paper
• Prognostic significance of occlusion length in recanalized chronic total occlusion lesion: a retrospective cohort study with 5-year follow-up

  2020cites this paper
• Plasma levels of miR-143 and miR-145 are associated with coronary in-stent restenosis within 1 year of follow-up after drug-eluting stent implantation

  2020cites this paper
• Machine Learning to Predict Stent Restenosis Based on Daily Demographic, Clinical, and Angiographic Characteristics.

  2020cites this paper
• Acute and Long-term Relocation of Minimal Lumen Area after Bioresorbable Scaffold or Metallic Stent Implantation.

  2019cites this paper
• Revascularization in Patients With Spontaneous Coronary Artery Dissection and ST-Segment Elevation Myocardial Infarction.

  2019cites this paper
• Incidence and predictors of target lesion failure in patients undergoing contemporary DES implantation-Individual patient data pooled analysis from 6 randomized controlled trials.

  2019cites this paper
• Differential cutoff points and clinical impact of stent parameters of various drug-eluting stents for predicting major adverse clinical events: An individual patient data pooled analysis of seven stent-specific registries and 17,068 patients.

  2019cites this paper
• MiR-93-5p is a novel predictor of coronary in-stent restenosis

  2019cites this paper
• Impact of subclinical hypothyroidism on clinical outcomes following percutaneous coronary intervention.

  2018cites this paper
• Epac1 deficiency inhibits basic fibroblast growth factor-mediated vascular smooth muscle cell migration

  2018cites this paper
• Risk assessment score for drug eluting stent restenosis

  2018cites this paper
• Drug-Eluting Balloons versus Second-Generation Drug-Eluting Stents for Treating In-Stent Restenosis in Coronary Heart Disease after PCI: A Meta-Analysis

  2018cites this paper
• 10 Effectiveness and Efficiency of Drug Eluting Stents

  2017cites this paper
• BARE METAL STENTS SIZE : CORRELATIONS WITH CORONARY STENT RESTENOSIS

  2017cites this paper
• Combining clinical and angiographic variables for estimating risk of target lesion revascularization after drug eluting stent placement.

  2017cites this paper
• Bioresorbable Vascular Scaffolds for the Treatment of Chronic Total Occlusions: An International Multicenter Registry

  2017cites this paper
• The role of angiographic follow-up after percutaneous coronary intervention.

  2016cites this paper
• Treatment of drug‐eluting stent restenosis: Comparison between drug‐eluting balloon versus second‐generation drug‐eluting stents from a retrospective observational study

  2016cites this paper
• Drug-eluting stents or balloon angioplasty for drug-eluting stent-associated restenosis: An observational follow-up study of first-time versus repeated restenosis

  2016cites this paper
• Bioresorbable scaffolds for the treatment of complex lesions: are we there yet?

  2015cites this paper
• Resolute zotarolimus eluting stent for treatment of long coronary lesions.

  2015cites this paper
• The relationship between the high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P) and coronary in-stent restenosis.

  2015cites this paper
• STUDY OF ANATOMIC AND LESION RELATED PREDICTIVE FACTORS OF IN STENT RESTENOSIS

  2015cites this paper
• The national society journals present selected research that has driven recent advances in

  2015cites this paper
• Drug-eluting balloon in the treatment of in-stent restenosis and diffuse coronary artery disease: real-world experience from our registry.

  2014cites this paper
• Predicting target vessel revascularization in older patients undergoing percutaneous coronary intervention in the drug-eluting stent era.

  2014cites this paper
• Immediate results and long-term clinical outcome of patients with unprotected distal left main restenosis: the CORPAL registry (Córdoba and Las Palmas).

  2014cites this paper
• Investigation of the effect of nitrite in the management and treatment of myocardial infarction

  2014cites this paper
• Extended follow‐up following “full‐metal jacket” percutaneous coronary interventions with drug‐eluting stents

  2014cites this paper
• Management of distal/bifurcation left main restenosis after drug eluting stents implantation: single center experience.

  2014cites this paper
• Nanomedicines for Restenosis Therapy

  2014cites this paper
• Chronic treatment with trimetazidine after discharge reduces the incidence of restenosis in patients who received coronary stent implantation: a 1-year prospective follow-up study.

  2014cites this paper
• 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention

  2013cites this paper
• A clinical evaluation of the ProNOVA XR polymer-free sirolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions (EURONOVA XR I study).

  2013cites this paper
• Genetic and pharmacogenetic determinants of cardiovascular disease

  2013cites this paper
• Chapter 11 – Advances in Coronary Revascularization

  2013cites this paper
• Can we bear another bare‐metal stent study?

  2013cites this paper
• Almanac 2012: Cardiovascular risk scores.

  2013cites this paper
• Almanac 2012: cardiovascular risk scores. The national society journals present selected research that has driven recent advances in clinical cardiology.

  2013cites this paper
• Restenosis after PCI pathophysiology and risk factors

  2013cites this paper
• Restenosis after PCI. prevention and therapy

  2013cites this paper
• lmanac 2012 : Cardiovascular risk scores lmanaque 2012 : Puntajes de riesgo cardiovascular ill

  2013cites this paper
• Processed B-type natriuretic peptide is a biomarker of postinterventional restenosis in ischemic heart disease.

  2013cites this paper
• Postoperative care and follow-up after coronary stenting.

  2013cites this paper
• Almanac 2012: cardiovascular risk scores. The journals present selected research that has driven recent advances in clinical cardiology.

  2013cites this paper
• The 'all comer' Coroflex Please drug-eluting stent registry in Europe and Asia - an overall and transcontinental assessment of the 10-month major adverse cardiac events.

  2012cites this paper
• Restenosis after PCI. Part 1: pathophysiology and risk factors

  2012cites this paper
• Ryzyko wystąpienia powikłań sercowo-naczyniowych w obserwacji odległej u pacjentów po implantacji stentów lekowych

  2012cites this paper
• Drug-Eluting Stent Restenosis: The PEPCAD-DES Study Paclitaxel-Coated Balloon Angioplasty With Plain Balloon Angioplasty in A Randomized, Multicenter, Single-Blinded Trial Comparing

  2012cites this paper
• Almanac 2012: Las Revistas de las Sociedades Nacionales presentan investigaciones seleccionadas que han determinado recientes avances en la cardiología clínica Scores de Riesgo Cardiovascular

  2012cites this paper
• Effectiveness and Efficiency of Drug Eluting Stents

  2012cites this paper
• A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study.

  2012cites this paper
• Almanac 2012: cardiovascular risk scores. The national society journals present selected research that has driven recent advances in clinical cardiology

  2012cites this paper
• Factors influencing the outcomes of percutaneous coronary intervention in the stent era

  2012cites this paper
• Impact of routine angiographic follow-up after percutaneous coronary intervention with drug-eluting stents in the SPIRIT III randomized trial at three years.

  2012cites this paper
• Restenosis after PCI. Part 2: prevention and therapy

  2012cites this paper
• 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary

  2012influential citation
• Clinical presentation and predictors of target vessel revascularization after drug-eluting stent implantation.

  2012influential citation
• Almanac 2012: cardiovascular risk scores. The National Society Journals present selected research that has driven recent advances in clinical cardiology.

  2012cites this paper
• Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions

  2011cites this paper
• Circulation: Cardiovascular Interventions Editors' Picks Most Important Papers in Coronary Stenting

  2011cites this paper
• Tarek Ahmed bw.indd

  2011cites this paper
• Stent Design Polymer-Free Biolimus A 9-Coated Stent Demonstrates More Sustained Intimal Inhibition , Improved Healing , and Reduced Inflammation Compared With a Polymer-Coated Sirolimus-Eluting Cypher Stent in a Porcine Model

  2011cites this paper
• Predicting the Restenosis Benefit of Drug-Eluting Versus Bare Metal Stents in Percutaneous Coronary Intervention

  2011cites this paper
• Rationale and design of the clinical evaluation of the Resolute Zotarolimus-Eluting Coronary Stent System in the treatment of de novo lesions in native coronary arteries (the RESOLUTE US clinical trial).

  2011cites this paper
• 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.

  2011cites this paper
• Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial.

  2011cites this paper
• 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.

  2011cites this paper
• RESOLUTE US Clinical Trial System in the Treatment of De Novo Lesions in Native Coronary Arteries: The Clinical Evaluation of the Resolute Zotarolimus-Eluting Coronary Stent

  2011cites this paper
• ACCF/AHA/SCAI Practice Guideline 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions

  2011cites this paper